221 related articles for article (PubMed ID: 22576334)
1. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.
Renard D; Castelnovo G; Wacongne A; Le Floch A; Thouvenot E; Mas J; Gabelle A; Labauge P; Lehmann S
J Neurol; 2012 Nov; 259(11):2429-33. PubMed ID: 22576334
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.
Renard D; Gabelle A; Hirtz C; Demattei C; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016 Oct; 54(4):1291-1295. PubMed ID: 27567848
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy.
Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D
J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.
Renard D; Wacongne A; Ayrignac X; Charif M; Fourcade G; Azakri S; Le Floch A; Bouly S; Marelli C; Arquizan C; Hirtz C; Gabelle A; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016; 50(3):759-764. PubMed ID: 26757185
[TBL] [Abstract][Full Text] [Related]
5. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
[TBL] [Abstract][Full Text] [Related]
7. Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy.
Dargvainiene J; Jensen-Kondering U; Bender B; Berg D; Brüggemann N; Flüh C; Markewitz R; Neumann A; Röben B; Röcken C; Royl G; Schulte C; Wandinger KP; Weiler C; Margraf NG; Kuhlenbäumer G
Ann Clin Transl Neurol; 2024 Mar; 11(3):806-811. PubMed ID: 38186185
[TBL] [Abstract][Full Text] [Related]
8. β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy.
van Etten ES; Verbeek MM; van der Grond J; Zielman R; van Rooden S; van Zwet EW; van Opstal AM; Haan J; Greenberg SM; van Buchem MA; Wermer MJ; Terwindt GM
Neurology; 2017 Jan; 88(2):169-176. PubMed ID: 27903811
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy.
Li YF; Ge FF; Zhang Y; You H; Zhang ZX
Chin Med Sci J; 2015 Sep; 30(3):170-3. PubMed ID: 26564416
[TBL] [Abstract][Full Text] [Related]
10. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
De Kort AM; Kuiperij HB; Marques TM; Jäkel L; van den Berg E; Kersten I; van Berckel-Smit HEP; Duering M; Stoops E; Abdo WF; Rasing I; Voigt S; Koemans EA; Kaushik K; Warren AD; Greenberg SM; Brinkmalm G; Terwindt GM; Wermer MJH; Schreuder FHBM; Klijn CJM; Verbeek MM
Ann Neurol; 2023 Jun; 93(6):1173-1186. PubMed ID: 36707720
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.
Margraf NG; Jensen-Kondering U; Weiler C; Leypoldt F; Maetzler W; Philippen S; Bartsch T; Flüh C; Röcken C; Möller B; Royl G; Neumann A; Brüggemann N; Roeben B; Schulte C; Bender B; Berg D; Kuhlenbäumer G
Front Aging Neurosci; 2022; 14():783996. PubMed ID: 35237145
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Biomarkers and Amyloid-β Elimination from the Brain in Cerebral Amyloid Angiopathy-Related Inflammation.
Sakai K; Noguchi-Shinohara M; Tanaka H; Ikeda T; Hamaguchi T; Kakita A; Yamada M; Ono K
J Alzheimers Dis; 2023; 91(3):1173-1183. PubMed ID: 36565118
[TBL] [Abstract][Full Text] [Related]
13. Cerebral Amyloid Angiopathy-Related Microbleeds and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease.
Noguchi-Shinohara M; Komatsu J; Samuraki M; Matsunari I; Ikeda T; Sakai K; Hamaguchi T; Ono K; Nakamura H; Yamada M
J Alzheimers Dis; 2017; 55(3):905-913. PubMed ID: 27802236
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
16. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
17. Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features.
Renard D; Tatu L; Collombier L; Wacongne A; Ayrignac X; Charif M; Boukriche Y; Chiper L; Fourcade G; Azakri S; Gaillard N; Mercier E; Lehmann S; Thouvenot E
J Alzheimers Dis; 2018; 64(4):1113-1121. PubMed ID: 30010128
[TBL] [Abstract][Full Text] [Related]
18. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
Biscetti L; Salvadori N; Farotti L; Cataldi S; Eusebi P; Paciotti S; Parnetti L
Clin Chim Acta; 2019 Jul; 494():71-73. PubMed ID: 30844364
[TBL] [Abstract][Full Text] [Related]
19. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
[TBL] [Abstract][Full Text] [Related]
20. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
de Kort AM; Kuiperij HB; Jäkel L; Kersten I; Rasing I; van Etten ES; van Rooden S; van Osch MJP; Wermer MJH; Terwindt GM; Schreuder FHBM; Klijn CJM; Verbeek MM
Alzheimers Res Ther; 2023 Jun; 15(1):102. PubMed ID: 37270536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
